The European Medicines Agency's Committee For Medicinal Products For Human Use Has Adopted A Positive Opinion, Recommending Approval Of Novo Nordisk's Alhemo (Concizumab) As The First Once-Daily Subcutaneous Prophylactic Treatment For People Aged 12 Years Or Older With Hemophilia A Or B With Inhibitors.
Portfolio Pulse from Benzinga Newsdesk
The European Medicines Agency's Committee has recommended approval of Novo Nordisk's Alhemo (Concizumab) for hemophilia A or B with inhibitors, marking it as the first once-daily subcutaneous prophylactic treatment for patients aged 12 and older.
October 18, 2024 | 10:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novo Nordisk's Alhemo (Concizumab) has received a positive opinion from the European Medicines Agency, recommending its approval as a treatment for hemophilia A or B with inhibitors. This could enhance Novo Nordisk's product portfolio and market position.
The recommendation for approval by the European Medicines Agency is a significant regulatory milestone for Novo Nordisk. It positions Alhemo as a pioneering treatment in the hemophilia market, potentially increasing Novo Nordisk's market share and revenue.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90